Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy

This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

Male

Study type

Observational

Primary location

Research Site, Baja, Hungary

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provision of informed consent
Early or locally-advanced prostate cancer patients on androgen deprivation therapy
Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment.

Exclusion criteria

Allergy to substance of medication
Prostate cancer patients with advanced disease

Treatment and study plan

Primary outcomes

Elements of a general and three disease-specific investigator questionnaire

Time frame: Quarterly (plus or minus 3 days )

Secondary outcomes

Investigator Assessment Report

Time frame: Yearly (plus or minus 1 week )

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Quality of Life Analysis of Prostate Cancer Patient's Therapy

Acronym: AZTEK EXT

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Jun 6, 2008
Registry last updated: Dec 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed